Coya Therapeutics (NASDAQ:COYA) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Coya Therapeutics (NASDAQ:COYA) from a sell rating to a hold rating in a research report sent to investors on Saturday.

COYA has been the topic of a number of other research reports. Chardan Capital reissued a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a research report on Monday, March 16th. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Coya Therapeutics in a research report on Monday, March 23rd. D. Boral Capital reissued a “buy” rating and set a $15.00 price target on shares of Coya Therapeutics in a research report on Friday, April 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Wednesday, January 21st. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Coya Therapeutics Stock Performance

COYA opened at $4.78 on Friday. Coya Therapeutics has a 52-week low of $3.71 and a 52-week high of $7.75. The firm has a market capitalization of $112.12 million, a PE ratio of -3.76 and a beta of 0.51. The business’s 50-day simple moving average is $4.53 and its 200 day simple moving average is $5.29.

Coya Therapeutics (NASDAQ:COYA) last announced its quarterly earnings results on Monday, March 16th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.26). The business had revenue of $3.96 million for the quarter, compared to analyst estimates of $1.93 million. Coya Therapeutics had a negative return on equity of 62.76% and a negative net margin of 267.13%. On average, research analysts forecast that Coya Therapeutics will post -1.15 earnings per share for the current year.

Hedge Funds Weigh In On Coya Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. acquired a new position in shares of Coya Therapeutics in the third quarter valued at approximately $28,000. CIBC Private Wealth Group LLC acquired a new position in shares of Coya Therapeutics in the fourth quarter valued at approximately $47,000. Occudo Quantitative Strategies LP acquired a new position in shares of Coya Therapeutics in the fourth quarter valued at approximately $66,000. Lantern Wealth Advisors LLC acquired a new position in shares of Coya Therapeutics in the third quarter valued at approximately $66,000. Finally, Oppenheimer & Co. Inc. acquired a new position in shares of Coya Therapeutics in the fourth quarter valued at approximately $81,000. Institutional investors and hedge funds own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.